1168003-34-6

Basic information

• Product Name: C₁₆H₁₀FNO₃
• CAS NO: 1168003-34-6
• Molecular Weight: 283.259
• Mol File: 1168003-34-6.mol

Chemical Properties

• CAS DataBase Reference: C₁₆H₁₀FNO₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₆H₁₀FNO₃(1168003-34-6)
• EPA Substance Registry System: C₁₆H₁₀FNO₃(1168003-34-6)

Safety Data

• Hazardous Substances Data: 1168003-34-6(Hazardous Substances Data)

Upstream product

• 394-32-1 1-(5-fluoro-2-hydroxyphenyl)ethan-1-one 
• 69155-76-6 6-fluorochromone-3-carboxaldehyde 
• 100-65-2 N-Phenylhydroxylamine 
• 405-51-6 4-fluorophenyl acetate 
• 371-41-5 4-Fluorophenol 

Downstream Products

• 1168003-68-6 C₁₆H₁₀FNO₃ 
• 1168003-64-2 2-(carboethoxymethyl)-3-ethylindole 
• 1168003-54-0 1-ethoxycarbonyl-3-(2'-hydroxy-5'-fluoro-benzoyl)-10-ethyl-benzo[b]indolizine 
• 14190-78-4 ethyl 2-(3-methyl-1H-indol-2-yl)acetate 
• 1168003-53-9 1-ethoxycarbonyl-3-(2'-hydroxy-5'-fluoro-benzoyl)-10-methyl-benzo[b]indolizine 

Relevant articles and documents

3-Formylchromone based topoisomerase IIα inhibitors: Discovery of potent leads

Substituted 3-formylchromones were synthesized and evaluated as inhibitors of the human DNA topoisomerase IIα (hTopo-IIα) enzyme. The results of the decatenation, relaxation and DNA intercalation assays revealed that the compounds (11b, 12a, 12b, 12d, 12e, 13a and 13b) exhibited potent inhibitory activity against the hTopo-IIα enzyme, and are nonintercalating agents. These compounds also possess significant in vitro cytotoxicity (LC50 ranges from 0.5-8.6 μM) against prostate (PC-3) cancerous cell line as seen in comparison to the standard drug etoposide. To further probe the plausible mode of action of 3-formylchromone derivatives, molecular docking studies have also been carried out, which showed that the compounds under investigation fitted well in the ATP binding pocket of hTopo-IIα enzyme with good docking scores and form nonbonding interactions with the crucial residues of the catalytic site. The Royal Society of Chemistry.

Chromanyl-isoxazolidines as Antibacterial agents: Synthesis, Biological Evaluation, Quantitative Structure Activity Relationship, and Molecular Docking Studies

Regio- and stereoselective 1,3-dipolar cycloadditions of C-(chrom-4-one-3-yl)-N-phenylnitrones (N) with different mono-substituted, disubstituted, and cyclic dipolarophiles were carried out to obtain substituted N-phenyl-3′-(chrom-4-one-3-yl)-isoxazolidines (1-40). All the synthesized compounds were assayed for their in vitro antibacterial activity and display significant inhibitory potential; in particular, compound 32 exhibited good inhibitory activity against Salmonella typhymurium-1 & Salmonella typhymurium-2 with minimum inhibitory concentration value of 1.56 μg/mL and also showed good potential against methicillin-resistant Staphylococcus aureus with minimum inhibitory concentration 3.12 μg/mL. Quantitative structure activity relationship investigations with stepwise multiple linear regression analysis and docking simulation studies have been performed for validation of the observed antibacterial potential of the investigated compounds for determination of the most important parameters regulating antibacterial activities.